153 related articles for article (PubMed ID: 27147083)
1. Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors.
Pajtler KW; Tippelt S; Siegler N; Reichling S; Zimmermann M; Mikasch R; Bode U; Gnekow A; Pietsch T; Benesch M; Rutkowski S; Fleischhack G
J Neurooncol; 2016 Jul; 128(3):463-71. PubMed ID: 27147083
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours.
Fleischhack G; Reif S; Hasan C; Jaehde U; Hettmer S; Bode U
Br J Cancer; 2001 Jun; 84(11):1453-9. PubMed ID: 11384092
[TBL] [Abstract][Full Text] [Related]
3. Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide.
Chamberlain MC
Pediatr Neurol; 2001 Feb; 24(2):117-21. PubMed ID: 11275460
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors.
Slavc I; Schuller E; Falger J; Günes M; Pillwein K; Czech T; Dietrich W; Rössler K; Dieckmann K; Prayer D; Hainfellner J
J Neurooncol; 2003 Sep; 64(3):239-47. PubMed ID: 14558599
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors.
Needle MN; Molloy PT; Geyer JR; Herman-Liu A; Belasco JB; Goldwein JW; Sutton L; Phillips PC
Med Pediatr Oncol; 1997 Jul; 29(1):28-32. PubMed ID: 9142202
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
7. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
[TBL] [Abstract][Full Text] [Related]
8. Response of recurrent medulloblastoma to low-dose oral etoposide.
Ashley DM; Meier L; Kerby T; Zalduondo FM; Friedman HS; Gajjar A; Kun L; Duffner PK; Smith S; Longee D
J Clin Oncol; 1996 Jun; 14(6):1922-7. PubMed ID: 8656261
[TBL] [Abstract][Full Text] [Related]
9. Etoposide-containing regimens with autologous bone marrow transplantation in children with malignant brain tumors.
Busca A; Miniero R; Besenzon L; Cordero di Montezemolo L; Cenni M; Fagioli F; Sandri A; Vassallo E; Ricardi U; Madon E
Childs Nerv Syst; 1997; 13(11-12):572-7. PubMed ID: 9454971
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).
Davidson A; Gowing R; Lowis S; Newell D; Lewis I; Dicks-Mireaux C; Pinkerton CR
Eur J Cancer; 1997 Oct; 33(11):1816-22. PubMed ID: 9470839
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
12. Oral etoposide for recurrent/progressive sarcomas of childhood.
Kebudi R; Görgün O; Ayan I
Pediatr Blood Cancer; 2004 Apr; 42(4):320-4. PubMed ID: 14966827
[TBL] [Abstract][Full Text] [Related]
13. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A; Chocholous M; Sabel M; Lassaletta A; Sterba J; Leblond P; Nysom K; Torsvik I; Chi SN; Perwein T; Jones N; Holm S; Nyman P; Mörse H; Öberg A; Weiler-Wichtl L; Leiss U; Haberler C; Schmook MT; Mayr L; Dieckmann K; Kool M; Gojo J; Azizi AA; André N; Kieran M; Slavc I
JAMA Oncol; 2023 Dec; 9(12):1688-1695. PubMed ID: 37883081
[TBL] [Abstract][Full Text] [Related]
14. [The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases].
Kanamori M; Kumabe T; Saito R; Yamashita Y; Sonoda Y; Tominaga T
No Shinkei Geka; 2010 Nov; 38(11):997-1005. PubMed ID: 21081811
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy for recurrent spinal cord ependymona.
Chamberlain MC
Cancer; 2002 Sep; 95(5):997-1002. PubMed ID: 12209682
[TBL] [Abstract][Full Text] [Related]
16. Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors.
Fiorillo A; Maggi G; Greco N; Migliorati R; D'Amico A; De Caro MD; Sabbatino MS; Buffardi F
J Neurooncol; 2004 Jan; 66(1-2):179-85. PubMed ID: 15015784
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Korones DN; Smith A; Foreman N; Bouffet E
Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359
[TBL] [Abstract][Full Text] [Related]
18. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
19. Ten-day schedule oral etoposide therapy in advanced childhood malignancies.
Schiavetti A; Varrasso G; Maurizi P; Cappelli C; Clerico A; Properzi E; Castello MA
J Pediatr Hematol Oncol; 2000; 22(2):119-24. PubMed ID: 10779024
[TBL] [Abstract][Full Text] [Related]
20. Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.
Jakacki RI; Foley MA; Horan J; Wang J; Kieran MW; Bowers DC; Bouffet E; Zacharoulis S; Gill SC
J Neurooncol; 2016 Aug; 129(1):131-8. PubMed ID: 27287856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
